These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28420840)

  • 1. Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.
    Matano D; Moriwaki T; Tange Y; Niisato Y; Yamaura M; Nagase M; Suganuma D; Takagi Taketa K; Iwai K; Enami C; Yamamoto Y; Hyodo I
    Intern Med; 2017; 56(8):921-923. PubMed ID: 28420840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
    Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
    Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
    Morifuji M; Murakami Y; Yokoyama Y; Sasaki M; Hayashidani Y; Toge K; Sueda T
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2027-30. PubMed ID: 15570933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
    Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
    Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
    Seo S; Suzuki T; Misumi T; Tashiro H
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1305-1307. PubMed ID: 29394615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
    Sato S; Kunisaki C; Tanaka Y; Sato K; Miyamoto H; Yukawa N; Fujii Y; Kimura J; Takagawa R; Takahashi M; Kosaka T; Akiyama H; Saigusa Y; Taguri M; Yamanaka T; Endo I
    Anticancer Res; 2018 Dec; 38(12):6911-6917. PubMed ID: 30504409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
    Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
    Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
    Ohashi M; Kanda T; Yajima K; Banba T; Tanabe T; Kosugi S; Hatakeyama K
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1640-2. PubMed ID: 16315894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
    Urano S; Kakiuchi Y; Takashima H
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):251-4. PubMed ID: 27067693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
    Seshimo K; Kanagawa T; Yamashita Y; Oishi M; Kodera M; Yamamura M; Katoh H; Ikeda H; Yokomichi N; Kobayashi K; Takita K
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1741-4. PubMed ID: 19838039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
    Kato K; Koide A; Oobu M; Hasegawa K; Maruyama S; Takashima I; Nagahama T; Maruyama M; Ebuchi M
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1852-4. PubMed ID: 15553737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of advanced gastric cancer with peritoneal metastases responding to bi-weekly paclitaxel therapy].
    Yamaguchi Y; Taniguchi K; Naka T; Shibata S; Ishiguro M; Yurugi E; Nishidoi H; Kudoh H; Murakami S
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):527-30. PubMed ID: 12722687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
    Fujii K; Uno H; Kayo S; Ueda Y; Kawamura C; Mizuyama Y; Kaneda K; Nakagawa H; Arakawa T
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1107-9. PubMed ID: 17637550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
    Okumura K; Tani S; Shiogai Y; Kodama M; Mekata E; Tan T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):667-70. PubMed ID: 22504699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.